PBM Rebate Reconciliation Explained

Rebate reconciliation is the process of auditing the rebates a PBM guaranteed in its contract against the rebates it actually paid to the plan sponsor. Most PBM contracts include rebate guarantees, minimum per-brand-claim dollar amounts the PBM commits to delivering, but verifying delivery requires line-by-line claims auditing. Without that audit, the gap between guaranteed and paid is invisible.

The gap is often material. In our work at TeliosRx, rebate reconciliation routinely identifies five- and six-figure underpayments on plans 1,000 lives and up. The PBM's own self-reported reconciliation typically shows the plan owed less than an independent reconciliation reveals. That gap is the reason this work exists.

What pharmacy rebates are

A drug manufacturer pays a rebate to a PBM (or to a rebate aggregator owned by or affiliated with the PBM) in exchange for placing the manufacturer's drug on the formulary at a preferred tier. The rebate is typically a per-claim or per-script dollar amount, sometimes a percentage of net sales, and sometimes a combination. Rebates are negotiated separately by drug, by manufacturer, and by formulary placement.

Rebates can be very large. For top brand drugs, manufacturer rebates often exceed 50% of the drug's list price. Specialty drugs frequently have rebates in the hundreds or thousands of dollars per script. Across a plan with significant brand and specialty spend, total rebate dollars often run into the millions.

The PBM collects these rebates from manufacturers and is supposed to pass them through to the plan sponsor according to the contract. The "supposed to" is where reconciliation matters.

How rebate guarantees are structured

Modern PBM contracts typically guarantee a minimum per-claim rebate by channel and drug category. A common structure looks like this:

These guarantees mean: the PBM commits to delivering at least $350 in manufacturer rebates per Brand-Retail-30 claim, on average across the contract year. If the actual delivered rebate is lower, the PBM owes the plan the difference.

Critically, the guarantees apply on an average, channel-netted basis, not per individual claim. The PBM is allowed to over-deliver on some claims and under-deliver on others, as long as the channel-level average meets the guarantee.

Why PBMs routinely underpay rebates

PBMs underpay rebate guarantees through several mechanisms. None of them are necessarily fraud. They're contract interpretations that always lean in the PBM's favor.

1. Exclusion creep. The contract excludes certain drugs from the rebate guarantee (compounds, OTC, 340B, etc.). Over the contract year, the PBM's interpretation of those exclusions tends to expand, pulling more drugs out of the guaranteed pool.

2. Channel-netting tricks. Many contracts use "sum of positive only" netting, where the PBM only owes the plan money when a channel underperforms. Overperformance in one channel doesn't offset underperformance in another from the plan's perspective.

3. Summary-to-detail variance. The PBM's own performance reconciliation report often doesn't match the underlying claim-level data. We routinely see PBM-reported rebate totals that are $20,000–$100,000 different from what a recalculation of the claim detail produces.

4. Aggregator opacity. When the PBM uses an affiliated rebate aggregator, the aggregator may keep a portion of the manufacturer rebate as an "administrative fee" before the rebate ever reaches the PBM.

5. Timing manipulation. Some manufacturer rebates are paid quarterly, some annually. The PBM controls which periods count toward which contract year's reconciliation. A rebate that should have applied to year one can be pushed into year two if it benefits the PBM.

The TeliosRx reconciliation process

A fiduciary rebate reconciliation follows a specific workflow:

1. Contract review. Identify the exact guarantee amounts by channel and drug category. Identify all exclusions, prerequisites, and qualifications.

2. Data ingestion. Pull claim-level data directly from the PBM, the rebate aggregator (where accessible), and the plan sponsor's own claims warehouse. Reconcile the three sources for completeness.

3. Channel classification. Apply the contract's channel definitions (Retail 30, Retail 90, Mail, Specialty) and drug category definitions (Brand, Generic) to each claim.

4. Per-claim rebate matching. For brand claims, identify the rebate that should have applied based on the manufacturer rebate agreement and the contract's rebate methodology.

5. Channel-level aggregation. Roll up rebate dollars by channel, compare against contracted guarantees, and identify any guarantee shortfall.

6. Exclusion verification. For every claim excluded from the rebate calculation, verify that the exclusion is justified by contract language, not by PBM interpretation drift.

7. Reconciliation report. Produce a clear, claim-level reconciliation showing guarantee, delivered, and gap by channel.

The process typically takes 3–6 weeks for a first-year reconciliation. Subsequent years go faster because the data infrastructure is already built.

Common findings

Pattern 1: Mail channel completely missing. The PBM's data extract excludes mail-order claims entirely. We've seen this on multiple recent engagements, it's a material control weakness regardless of the dollar impact.

Pattern 2: Specialty rebate shortfall. Specialty rebate guarantees are very high (often $3,000+ per claim). PBMs sometimes underperform their specialty rebate guarantee by 10–30%, six-figure shortfalls quickly.

Pattern 3: Summary-to-detail variance. The PBM's reported rebate total doesn't match what the underlying claim detail produces. The variance is always in the PBM's favor.

Pattern 4: Connect-program offset. The contract allows the PBM to net "Connect Program savings" against the rebate shortfall. The Connect Program savings number is calculated by the PBM and is often overstated.

The contractual remedy

When reconciliation identifies a rebate shortfall, the remedy is typically straightforward. The contract says the PBM owes the difference between guaranteed and delivered rebates. The plan invoices the PBM for that amount, and the PBM pays.

Where it gets complicated is when the contract has a liability cap, or when the PBM disputes the methodology. A fiduciary consultant negotiates these disputes on the plan's behalf, and ideally, has anticipated the dispute language in the original contract review.

How to prevent rebate underpayment in next year's contract

Most rebate underpayment is preventable at contract negotiation. The remedies are:

• True net reconciliation (not sum-of-positive only)
• Specific, exhaustive definitions of excluded drugs (not "as determined by PBM")
• Right to audit pharmacy-paid and rebate-aggregator data, not just PBM-reported summaries
• Reconciliation within 180 days of year-end (not 270+ days)
• 18-month claim runout cooperation after termination
• No liability cap on guarantee recovery, or at minimum a 5× admin fee cap

The takeaway

Rebate reconciliation is the single highest-ROI piece of PBM oversight work most plans don't do. The dollars are large, the work is tractable, and the contractual remedies are clear. Plans that reconcile every year recover real money. Plans that rely on the PBM's self-reported numbers don't.